nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—Pain—Cisplatin—testicular cancer	0.00134	0.00134	CcSEcCtD
Rifaximin—Dermatitis—Bleomycin—testicular cancer	0.00134	0.00134	CcSEcCtD
Rifaximin—Hypersensitivity—Ifosfamide—testicular cancer	0.00134	0.00134	CcSEcCtD
Rifaximin—Dysuria—Epirubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Rifaximin—Neutropenia—Epirubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Rifaximin—Abdominal distension—Doxorubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Epirubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Rifaximin—Dysphagia—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Rifaximin—Pollakiuria—Epirubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Rifaximin—Asthenia—Ifosfamide—testicular cancer	0.00131	0.00131	CcSEcCtD
Rifaximin—Photosensitivity reaction—Epirubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Rifaximin—Feeling abnormal—Cisplatin—testicular cancer	0.00129	0.00129	CcSEcCtD
Rifaximin—Weight increased—Epirubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Rifaximin—Pruritus—Ifosfamide—testicular cancer	0.00129	0.00129	CcSEcCtD
Rifaximin—Haematuria—Methotrexate—testicular cancer	0.00129	0.00129	CcSEcCtD
Rifaximin—Weight decreased—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Rifaximin—Dyspnoea—Etoposide—testicular cancer	0.00128	0.00128	CcSEcCtD
Rifaximin—Hyperglycaemia—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Rifaximin—Epistaxis—Methotrexate—testicular cancer	0.00127	0.00127	CcSEcCtD
Rifaximin—Pneumonia—Epirubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Rifaximin—Nausea—Bleomycin—testicular cancer	0.00127	0.00127	CcSEcCtD
Rifaximin—Infestation NOS—Epirubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Rifaximin—Infestation—Epirubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Rifaximin—Vomiting—Dactinomycin—testicular cancer	0.00126	0.00126	CcSEcCtD
Rifaximin—Rash—Dactinomycin—testicular cancer	0.00125	0.00125	CcSEcCtD
Rifaximin—Decreased appetite—Etoposide—testicular cancer	0.00125	0.00125	CcSEcCtD
Rifaximin—Diarrhoea—Ifosfamide—testicular cancer	0.00125	0.00125	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Etoposide—testicular cancer	0.00124	0.00124	CcSEcCtD
Rifaximin—Body temperature increased—Cisplatin—testicular cancer	0.00124	0.00124	CcSEcCtD
Rifaximin—Fatigue—Etoposide—testicular cancer	0.00124	0.00124	CcSEcCtD
Rifaximin—Constipation—Etoposide—testicular cancer	0.00123	0.00123	CcSEcCtD
Rifaximin—Pain—Etoposide—testicular cancer	0.00123	0.00123	CcSEcCtD
Rifaximin—Dysuria—Doxorubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Rifaximin—Neutropenia—Doxorubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Rifaximin—Haemoglobin—Methotrexate—testicular cancer	0.00122	0.00122	CcSEcCtD
Rifaximin—Haemorrhage—Methotrexate—testicular cancer	0.00121	0.00121	CcSEcCtD
Rifaximin—Pollakiuria—Doxorubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Rifaximin—Haematuria—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Rifaximin—Dizziness—Ifosfamide—testicular cancer	0.0012	0.0012	CcSEcCtD
Rifaximin—Pharyngitis—Methotrexate—testicular cancer	0.0012	0.0012	CcSEcCtD
Rifaximin—Urinary tract disorder—Methotrexate—testicular cancer	0.0012	0.0012	CcSEcCtD
Rifaximin—Photosensitivity reaction—Doxorubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Rifaximin—Weight increased—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Rifaximin—Epistaxis—Epirubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Rifaximin—Urethral disorder—Methotrexate—testicular cancer	0.00119	0.00119	CcSEcCtD
Rifaximin—Weight decreased—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Rifaximin—Feeling abnormal—Etoposide—testicular cancer	0.00118	0.00118	CcSEcCtD
Rifaximin—Hyperglycaemia—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Rifaximin—Nausea—Dactinomycin—testicular cancer	0.00118	0.00118	CcSEcCtD
Rifaximin—Pneumonia—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Rifaximin—Gastrointestinal pain—Etoposide—testicular cancer	0.00118	0.00118	CcSEcCtD
Rifaximin—Infestation NOS—Doxorubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Rifaximin—Infestation—Doxorubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Rifaximin—Vomiting—Ifosfamide—testicular cancer	0.00116	0.00116	CcSEcCtD
Rifaximin—Hypersensitivity—Cisplatin—testicular cancer	0.00116	0.00116	CcSEcCtD
Rifaximin—Rash—Ifosfamide—testicular cancer	0.00115	0.00115	CcSEcCtD
Rifaximin—Dermatitis—Ifosfamide—testicular cancer	0.00115	0.00115	CcSEcCtD
Rifaximin—Urticaria—Etoposide—testicular cancer	0.00114	0.00114	CcSEcCtD
Rifaximin—Haemoglobin—Epirubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Rifaximin—Rhinitis—Epirubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Rifaximin—Abdominal pain—Etoposide—testicular cancer	0.00114	0.00114	CcSEcCtD
Rifaximin—Body temperature increased—Etoposide—testicular cancer	0.00114	0.00114	CcSEcCtD
Rifaximin—Haemorrhage—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Rifaximin—Tinnitus—Methotrexate—testicular cancer	0.00113	0.00113	CcSEcCtD
Rifaximin—Hypoaesthesia—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Rifaximin—Asthenia—Cisplatin—testicular cancer	0.00113	0.00113	CcSEcCtD
Rifaximin—Pharyngitis—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Rifaximin—Urinary tract disorder—Epirubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Rifaximin—Oedema peripheral—Epirubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Rifaximin—Haematuria—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Rifaximin—Urethral disorder—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Rifaximin—Epistaxis—Doxorubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Rifaximin—Angiopathy—Methotrexate—testicular cancer	0.0011	0.0011	CcSEcCtD
Rifaximin—Mediastinal disorder—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Rifaximin—Nausea—Ifosfamide—testicular cancer	0.00108	0.00108	CcSEcCtD
Rifaximin—Diarrhoea—Cisplatin—testicular cancer	0.00107	0.00107	CcSEcCtD
Rifaximin—Mental disorder—Methotrexate—testicular cancer	0.00106	0.00106	CcSEcCtD
Rifaximin—Hypersensitivity—Etoposide—testicular cancer	0.00106	0.00106	CcSEcCtD
Rifaximin—Tinnitus—Epirubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Rifaximin—Malnutrition—Methotrexate—testicular cancer	0.00106	0.00106	CcSEcCtD
Rifaximin—Haemoglobin—Doxorubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Rifaximin—Flushing—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Rifaximin—Rhinitis—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Rifaximin—Haemorrhage—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Rifaximin—Urinary tract disorder—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Rifaximin—Asthenia—Etoposide—testicular cancer	0.00103	0.00103	CcSEcCtD
Rifaximin—Angiopathy—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Rifaximin—Mediastinal disorder—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Rifaximin—Back pain—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Rifaximin—Pruritus—Etoposide—testicular cancer	0.00102	0.00102	CcSEcCtD
Rifaximin—Vomiting—Cisplatin—testicular cancer	0.000998	0.000998	CcSEcCtD
Rifaximin—Mental disorder—Epirubicin—testicular cancer	0.000994	0.000994	CcSEcCtD
Rifaximin—Rash—Cisplatin—testicular cancer	0.00099	0.00099	CcSEcCtD
Rifaximin—Dermatitis—Cisplatin—testicular cancer	0.000989	0.000989	CcSEcCtD
Rifaximin—Malnutrition—Epirubicin—testicular cancer	0.000988	0.000988	CcSEcCtD
Rifaximin—Diarrhoea—Etoposide—testicular cancer	0.000984	0.000984	CcSEcCtD
Rifaximin—Ill-defined disorder—Methotrexate—testicular cancer	0.000979	0.000979	CcSEcCtD
Rifaximin—Tinnitus—Doxorubicin—testicular cancer	0.000979	0.000979	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—testicular cancer	0.000975	0.000975	CcSEcCtD
Rifaximin—Flushing—Doxorubicin—testicular cancer	0.000974	0.000974	CcSEcCtD
Rifaximin—Flatulence—Epirubicin—testicular cancer	0.000973	0.000973	CcSEcCtD
Rifaximin—Back pain—Epirubicin—testicular cancer	0.000955	0.000955	CcSEcCtD
Rifaximin—Angiopathy—Doxorubicin—testicular cancer	0.000952	0.000952	CcSEcCtD
Rifaximin—Malaise—Methotrexate—testicular cancer	0.000952	0.000952	CcSEcCtD
Rifaximin—Dizziness—Etoposide—testicular cancer	0.000951	0.000951	CcSEcCtD
Rifaximin—Muscle spasms—Epirubicin—testicular cancer	0.000949	0.000949	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—testicular cancer	0.000948	0.000948	CcSEcCtD
Rifaximin—Mediastinal disorder—Doxorubicin—testicular cancer	0.000946	0.000946	CcSEcCtD
Rifaximin—Nausea—Cisplatin—testicular cancer	0.000932	0.000932	CcSEcCtD
Rifaximin—Cough—Methotrexate—testicular cancer	0.000921	0.000921	CcSEcCtD
Rifaximin—Mental disorder—Doxorubicin—testicular cancer	0.00092	0.00092	CcSEcCtD
Rifaximin—Ill-defined disorder—Epirubicin—testicular cancer	0.000916	0.000916	CcSEcCtD
Rifaximin—Vomiting—Etoposide—testicular cancer	0.000914	0.000914	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—testicular cancer	0.000914	0.000914	CcSEcCtD
Rifaximin—Anaemia—Epirubicin—testicular cancer	0.000913	0.000913	CcSEcCtD
Rifaximin—Rash—Etoposide—testicular cancer	0.000907	0.000907	CcSEcCtD
Rifaximin—Dermatitis—Etoposide—testicular cancer	0.000906	0.000906	CcSEcCtD
Rifaximin—Headache—Etoposide—testicular cancer	0.000901	0.000901	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—testicular cancer	0.0009	0.0009	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—testicular cancer	0.000898	0.000898	CcSEcCtD
Rifaximin—Arthralgia—Methotrexate—testicular cancer	0.000898	0.000898	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—testicular cancer	0.000898	0.000898	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000892	0.000892	CcSEcCtD
Rifaximin—Malaise—Epirubicin—testicular cancer	0.000891	0.000891	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—testicular cancer	0.000888	0.000888	CcSEcCtD
Rifaximin—Vertigo—Epirubicin—testicular cancer	0.000887	0.000887	CcSEcCtD
Rifaximin—Syncope—Epirubicin—testicular cancer	0.000886	0.000886	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—testicular cancer	0.000884	0.000884	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—testicular cancer	0.000879	0.000879	CcSEcCtD
Rifaximin—Confusional state—Methotrexate—testicular cancer	0.000868	0.000868	CcSEcCtD
Rifaximin—Loss of consciousness—Epirubicin—testicular cancer	0.000868	0.000868	CcSEcCtD
Rifaximin—Cough—Epirubicin—testicular cancer	0.000862	0.000862	CcSEcCtD
Rifaximin—Anaphylactic shock—Methotrexate—testicular cancer	0.000861	0.000861	CcSEcCtD
Rifaximin—Infection—Methotrexate—testicular cancer	0.000856	0.000856	CcSEcCtD
Rifaximin—Nausea—Etoposide—testicular cancer	0.000854	0.000854	CcSEcCtD
Rifaximin—Ill-defined disorder—Doxorubicin—testicular cancer	0.000848	0.000848	CcSEcCtD
Rifaximin—Nervous system disorder—Methotrexate—testicular cancer	0.000845	0.000845	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—testicular cancer	0.000845	0.000845	CcSEcCtD
Rifaximin—Arthralgia—Epirubicin—testicular cancer	0.000841	0.000841	CcSEcCtD
Rifaximin—Myalgia—Epirubicin—testicular cancer	0.000841	0.000841	CcSEcCtD
Rifaximin—Chest pain—Epirubicin—testicular cancer	0.000841	0.000841	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—testicular cancer	0.000837	0.000837	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000835	0.000835	CcSEcCtD
Rifaximin—Hyperhidrosis—Methotrexate—testicular cancer	0.000833	0.000833	CcSEcCtD
Rifaximin—Discomfort—Epirubicin—testicular cancer	0.000831	0.000831	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—testicular cancer	0.000824	0.000824	CcSEcCtD
Rifaximin—Dry mouth—Epirubicin—testicular cancer	0.000822	0.000822	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—testicular cancer	0.000821	0.000821	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—testicular cancer	0.000821	0.000821	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—testicular cancer	0.000819	0.000819	CcSEcCtD
Rifaximin—Confusional state—Epirubicin—testicular cancer	0.000813	0.000813	CcSEcCtD
Rifaximin—Anaphylactic shock—Epirubicin—testicular cancer	0.000806	0.000806	CcSEcCtD
Rifaximin—Hypotension—Methotrexate—testicular cancer	0.000805	0.000805	CcSEcCtD
Rifaximin—Loss of consciousness—Doxorubicin—testicular cancer	0.000803	0.000803	CcSEcCtD
Rifaximin—Infection—Epirubicin—testicular cancer	0.000801	0.000801	CcSEcCtD
Rifaximin—Cough—Doxorubicin—testicular cancer	0.000797	0.000797	CcSEcCtD
Rifaximin—Shock—Epirubicin—testicular cancer	0.000793	0.000793	CcSEcCtD
Rifaximin—Nervous system disorder—Epirubicin—testicular cancer	0.00079	0.00079	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000785	0.000785	CcSEcCtD
Rifaximin—Skin disorder—Epirubicin—testicular cancer	0.000783	0.000783	CcSEcCtD
Rifaximin—Hyperhidrosis—Epirubicin—testicular cancer	0.000779	0.000779	CcSEcCtD
Rifaximin—Insomnia—Methotrexate—testicular cancer	0.000779	0.000779	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—testicular cancer	0.000778	0.000778	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—testicular cancer	0.000778	0.000778	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—testicular cancer	0.000778	0.000778	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000773	0.000773	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—testicular cancer	0.000769	0.000769	CcSEcCtD
Rifaximin—Anorexia—Epirubicin—testicular cancer	0.000768	0.000768	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—testicular cancer	0.000768	0.000768	CcSEcCtD
Rifaximin—Dry mouth—Doxorubicin—testicular cancer	0.000761	0.000761	CcSEcCtD
Rifaximin—Hypotension—Epirubicin—testicular cancer	0.000753	0.000753	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—testicular cancer	0.000752	0.000752	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—testicular cancer	0.000749	0.000749	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—testicular cancer	0.000746	0.000746	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000744	0.000744	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—testicular cancer	0.000743	0.000743	CcSEcCtD
Rifaximin—Infection—Doxorubicin—testicular cancer	0.000741	0.000741	CcSEcCtD
Rifaximin—Pain—Methotrexate—testicular cancer	0.000736	0.000736	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000734	0.000734	CcSEcCtD
Rifaximin—Shock—Doxorubicin—testicular cancer	0.000734	0.000734	CcSEcCtD
Rifaximin—Nervous system disorder—Doxorubicin—testicular cancer	0.000731	0.000731	CcSEcCtD
Rifaximin—Insomnia—Epirubicin—testicular cancer	0.000729	0.000729	CcSEcCtD
Rifaximin—Skin disorder—Doxorubicin—testicular cancer	0.000724	0.000724	CcSEcCtD
Rifaximin—Hyperhidrosis—Doxorubicin—testicular cancer	0.000721	0.000721	CcSEcCtD
Rifaximin—Dyspnoea—Epirubicin—testicular cancer	0.000719	0.000719	CcSEcCtD
Rifaximin—Anorexia—Doxorubicin—testicular cancer	0.000711	0.000711	CcSEcCtD
Rifaximin—Feeling abnormal—Methotrexate—testicular cancer	0.00071	0.00071	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—testicular cancer	0.000704	0.000704	CcSEcCtD
Rifaximin—Decreased appetite—Epirubicin—testicular cancer	0.000701	0.000701	CcSEcCtD
Rifaximin—Hypotension—Doxorubicin—testicular cancer	0.000697	0.000697	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000696	0.000696	CcSEcCtD
Rifaximin—Fatigue—Epirubicin—testicular cancer	0.000695	0.000695	CcSEcCtD
Rifaximin—Pain—Epirubicin—testicular cancer	0.000689	0.000689	CcSEcCtD
Rifaximin—Constipation—Epirubicin—testicular cancer	0.000689	0.000689	CcSEcCtD
Rifaximin—Urticaria—Methotrexate—testicular cancer	0.000684	0.000684	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—testicular cancer	0.000681	0.000681	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—testicular cancer	0.000681	0.000681	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000679	0.000679	CcSEcCtD
Rifaximin—Insomnia—Doxorubicin—testicular cancer	0.000675	0.000675	CcSEcCtD
Rifaximin—Dyspnoea—Doxorubicin—testicular cancer	0.000665	0.000665	CcSEcCtD
Rifaximin—Feeling abnormal—Epirubicin—testicular cancer	0.000664	0.000664	CcSEcCtD
Rifaximin—Gastrointestinal pain—Epirubicin—testicular cancer	0.000659	0.000659	CcSEcCtD
Rifaximin—Decreased appetite—Doxorubicin—testicular cancer	0.000648	0.000648	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000644	0.000644	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—testicular cancer	0.000643	0.000643	CcSEcCtD
Rifaximin—Urticaria—Epirubicin—testicular cancer	0.00064	0.00064	CcSEcCtD
Rifaximin—Pain—Doxorubicin—testicular cancer	0.000638	0.000638	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—testicular cancer	0.000638	0.000638	CcSEcCtD
Rifaximin—Abdominal pain—Epirubicin—testicular cancer	0.000637	0.000637	CcSEcCtD
Rifaximin—Body temperature increased—Epirubicin—testicular cancer	0.000637	0.000637	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—testicular cancer	0.000635	0.000635	CcSEcCtD
Rifaximin—Asthenia—Methotrexate—testicular cancer	0.000618	0.000618	CcSEcCtD
Rifaximin—Feeling abnormal—Doxorubicin—testicular cancer	0.000615	0.000615	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00061	0.00061	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—testicular cancer	0.000609	0.000609	CcSEcCtD
Rifaximin—Hypersensitivity—Epirubicin—testicular cancer	0.000594	0.000594	CcSEcCtD
Rifaximin—Urticaria—Doxorubicin—testicular cancer	0.000592	0.000592	CcSEcCtD
Rifaximin—Abdominal pain—Doxorubicin—testicular cancer	0.00059	0.00059	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—testicular cancer	0.00059	0.00059	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—testicular cancer	0.000589	0.000589	CcSEcCtD
Rifaximin—Asthenia—Epirubicin—testicular cancer	0.000578	0.000578	CcSEcCtD
Rifaximin—Pruritus—Epirubicin—testicular cancer	0.00057	0.00057	CcSEcCtD
Rifaximin—Dizziness—Methotrexate—testicular cancer	0.00057	0.00057	CcSEcCtD
Rifaximin—Diarrhoea—Epirubicin—testicular cancer	0.000551	0.000551	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—testicular cancer	0.000549	0.000549	CcSEcCtD
Rifaximin—Vomiting—Methotrexate—testicular cancer	0.000548	0.000548	CcSEcCtD
Rifaximin—Rash—Methotrexate—testicular cancer	0.000543	0.000543	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—testicular cancer	0.000543	0.000543	CcSEcCtD
Rifaximin—Headache—Methotrexate—testicular cancer	0.00054	0.00054	CcSEcCtD
Rifaximin—Asthenia—Doxorubicin—testicular cancer	0.000535	0.000535	CcSEcCtD
Rifaximin—Dizziness—Epirubicin—testicular cancer	0.000533	0.000533	CcSEcCtD
Rifaximin—Pruritus—Doxorubicin—testicular cancer	0.000528	0.000528	CcSEcCtD
Rifaximin—Vomiting—Epirubicin—testicular cancer	0.000512	0.000512	CcSEcCtD
Rifaximin—Nausea—Methotrexate—testicular cancer	0.000512	0.000512	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—testicular cancer	0.00051	0.00051	CcSEcCtD
Rifaximin—Rash—Epirubicin—testicular cancer	0.000508	0.000508	CcSEcCtD
Rifaximin—Dermatitis—Epirubicin—testicular cancer	0.000508	0.000508	CcSEcCtD
Rifaximin—Headache—Epirubicin—testicular cancer	0.000505	0.000505	CcSEcCtD
Rifaximin—Dizziness—Doxorubicin—testicular cancer	0.000493	0.000493	CcSEcCtD
Rifaximin—Nausea—Epirubicin—testicular cancer	0.000479	0.000479	CcSEcCtD
Rifaximin—Vomiting—Doxorubicin—testicular cancer	0.000474	0.000474	CcSEcCtD
Rifaximin—Rash—Doxorubicin—testicular cancer	0.00047	0.00047	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—testicular cancer	0.00047	0.00047	CcSEcCtD
Rifaximin—Headache—Doxorubicin—testicular cancer	0.000467	0.000467	CcSEcCtD
Rifaximin—Nausea—Doxorubicin—testicular cancer	0.000443	0.000443	CcSEcCtD
